2nd Circ. Product-Hopping Ruling May Prompt More Suits
When the Second Circuit hears arguments next month over whether Actavis PLC should be allowed to pull the older version of Namenda off the shelves before generic-drug competitors can enter the...To view the full article, register now.
Already a subscriber? Click here to view full article